XBIO Stock Xenetic Biosciences (XBIO, $2.91) price exceeded its 50-day Moving Average on May 16, 2025

GET DAILY SIGNALS

Get AI intraday signals

XBIO - Xenetic Biosciences

Moving Avg. signal

View

Odds of DOWN Trend

Price: $2.91

Daily change: -$0.1 (-3.32%)

Daily volume: 12.7K

Capitalization: $4.5M

Industry: Biotechnology

XBIO in -6.73% downward trend, falling for three consecutive days on May 16, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XBIO declined for three days, in of 329 cases, the price declined further within the following month. The odds of a continued downward trend are .

Technical Analysis (Indicators)

Bearish Trend Analysis

XBIO moved below its 50-day moving average on May 16, 2025 date and that indicates a change from an upward trend to a downward trend.

Bullish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.907) is normal, around the industry mean (16.954). P/E Ratio (0.000) is within average values for comparable stocks, (59.376). XBIO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.335). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (1.799) is also within normal values, averaging (257.043).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. XBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.